- Home
- RARE vs BDC Comparison
RARE vs BDC Comparison
Compare RARE & BDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- BDC
- Stock Information
- Founded
- RARE 2010
- BDC 1902
- Country
- RARE United States
- BDC United States
- Employees
- RARE N/A
- BDC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- BDC Telecommunications Equipment
- Sector
- RARE Health Care
- BDC Telecommunications
- Exchange
- RARE Nasdaq
- BDC Nasdaq
- Market Cap
- RARE 5.2B
- BDC 4.9B
- IPO Year
- RARE 2014
- BDC 1993
- Fundamental
- Price
- RARE $43.98
- BDC $113.76
- Analyst Decision
- RARE Strong Buy
- BDC Strong Buy
- Analyst Count
- RARE 14
- BDC 4
- Target Price
- RARE $88.43
- BDC $122.75
- AVG Volume (30 Days)
- RARE 717.6K
- BDC 274.1K
- Earning Date
- RARE 02-13-2025
- BDC 02-06-2025
- Dividend Yield
- RARE N/A
- BDC 0.18%
- EPS Growth
- RARE N/A
- BDC N/A
- EPS
- RARE N/A
- BDC 4.29
- Revenue
- RARE $522,745,000.00
- BDC $2,346,180,000.00
- Revenue This Year
- RARE $27.36
- BDC N/A
- Revenue Next Year
- RARE $18.61
- BDC $11.93
- P/E Ratio
- RARE N/A
- BDC $26.48
- Revenue Growth
- RARE 27.44
- BDC N/A
- 52 Week Low
- RARE $37.02
- BDC $71.20
- 52 Week High
- RARE $60.37
- BDC $131.82
- Technical
- Relative Strength Index (RSI)
- RARE 33.50
- BDC 37.14
- Support Level
- RARE $41.45
- BDC $112.84
- Resistance Level
- RARE $50.00
- BDC $124.35
- Average True Range (ATR)
- RARE 1.83
- BDC 3.30
- MACD
- RARE -0.31
- BDC -1.14
- Stochastic Oscillator
- RARE 26.55
- BDC 7.63
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About BDC Belden Inc
Belden Inc provides signal transmission products to distributors, end-users, installers, and original equipment manufacturers. The firm operates in two segments - Enterprise Solutions and Industrial Solutions. The Enterprise Solutions segment is a provider in network infrastructure solutions, as well as cabling and connectivity solutions for commercial audio/video and security applications. The Industrial Solutions segment is a provider of high-performance networking components and machine connectivity products. It operates in Americas, EMEA and APAC, out of which maximum revenue from Americas.